Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several mortality/all-cause mortality claims are consistent with the label (direction of imbalance and pooled adjusted risk difference). However, multiple additional mortality/etiology/statistical details in the AI claims are not supported by the supplied label excerpts (e.g., exact trial percentages without label citation, and attribution of drivers).
Category Scores
Accurate Statements
The FDA mandates black box warnings for increased all-cause mortality risk with tigecycline.
Supported in principle by the label excerpt: 'increase in all-cause mortality has been observed...' and 'TYGACIL should be reserved... [see BOXED Warning]'. (Exact black box text not provided in excerpt, but boxed-warning reference exists.)
Tigecycline trials showed 5.5% all-cause mortality versus 4.5% in comparators.
Not supported by the provided label excerpt for the cited comparison (label provides 4.0% vs 3.0% in Phase 3/4 comparator trials, and 2.5% vs 1.8% in approved-indication trials).
The FDA updated tigecycline labels in 2010 and 2013 to contraindicate monotherapy for hospital-acquired pneumonia.
Not supported by the provided label excerpts (timing/year and specific wording about contraindication not present).
Unsupported Statements
Tigecycline commonly causes nausea in up to 26% of patients.
No nausea incidence information is present in the provided label excerpts.
Tigecycline commonly causes vomiting in 18% of patients.
No vomiting incidence information is present in the provided label excerpts.
Tigecycline commonly causes diarrhea in 12% of patients.
No diarrhea incidence information is present in the provided label excerpts.
Gastrointestinal issues with tigecycline lead to treatment discontinuation in about 4% of cases.
No treatment discontinuation incidence information is present in the provided label excerpts.
Tigecycline trials showed 5.5% all-cause mortality versus 4.5% in comparators.
The label excerpt provides different mortality figures (e.g., 4.0% vs 3.0% in Phase 3/4 comparator trials; 2.5% vs 1.8% in approved-indication trials).
The higher mortality with tigecycline is driven by higher rates of septic shock and respiratory failure.
The label excerpt states the cause of the mortality imbalance 'has not been established' and does not attribute it to septic shock/respiratory failure.
Tigecycline is linked to superinfections such as Clostridium difficile-associated diarrhea due to broad-spectrum disruption of gut flora.
No statements in the provided label excerpts address C. difficile or gut flora disruption.
Tigecycline is linked to superinfections such as fungal infections due to broad-spectrum disruption of gut flora.
No statements in the provided label excerpts address fungal superinfections or gut flora disruption.
Pancreatitis occurs in 1–2% of tigecycline users.
No pancreatitis incidence information is present in the provided label excerpts.
Pancreatitis with tigecycline can be fatal.
No pancreatitis fatality information is present in the provided label excerpts.
Tigecycline shows reduced effectiveness against bacteremia.
No bacteremia effectiveness information is present in the provided label excerpts.
Tigecycline shows reduced effectiveness against severe pneumonia.
The excerpt discusses lack of efficacy in a trial of hospital/ventilator-associated pneumonia, but does not specifically quantify 'severe pneumonia' beyond the trial context; claim is broader than provided support.
The FDA updated tigecycline labels in 2010 and 2013 to contraindicate monotherapy for ventilator-associated pneumonia.
No year/timing information and no specific 'contraindicate monotherapy' phrasing for ventilator-associated pneumonia is present in the provided label excerpts.
Contraindication of tigecycline monotherapy for hospital-acquired/ventilator-associated pneumonia is due to higher mortality.
The excerpt states 'greater mortality and decreased efficacy were reported' but does not explicitly frame contraindications as being 'due to' higher mortality.
Bloodstream infections worsen outcomes with tigecycline compared with alternatives like imipenem.
The excerpt mentions high mortality among ventilator-associated pneumonia patients with bacteremia at baseline, but does not mention imipenem or compare to it.
Tigecycline is pregnancy category D with risks of fetal harm.
No pregnancy category information is present in the provided label excerpts.
Tigecycline requires a 100 mg loading dose.
The excerpt mentions trial dosing in the hospital/ventilator-associated pneumonia trial ('100 mg initially, then 50 mg every 12 hours'), but it does not establish a general requirement for a loading dose across all indications/dosing.
After the 100 mg loading dose, tigecycline is given as 50 mg every 12 hours.
Supported only for the pneumonia trial described, not as a general label dosing regimen in the provided excerpts.
Tigecycline use can lead to subtherapeutic levels in some tissues.
No pharmacokinetic/tissue-level statements are present in the provided label excerpts.
Tigecycline is associated with higher peak-related toxicity.
No peak-related toxicity statements are present in the provided label excerpts.
Tigecycline resistance can emerge via efflux pumps.
No resistance mechanism information is present in the provided label excerpts.
Tigecycline resistance can emerge via ribosomal mutations.
No resistance mechanism information is present in the provided label excerpts.
Emergence of tigecycline resistance limits long-term utility in multidrug-resistant infections.
No long-term utility/resistance impact statements are present in the provided label excerpts.
Tigecycline (Tygacil) is a branded product.
The label excerpt provided does not address branding/generic status.
Tigecycline is expensive, around $1,000–$2,000 per course.
No pricing information is present in the provided label excerpts.
There is no generic competition for tigecycline until patents expire.
No patent/generic-market information is present in the provided label excerpts.
Some tigecycline formulations have patent expiry in 2025.
No patent-expiry information is present in the provided label excerpts.
Tigecycline is an intravenous glycylcycline antibiotic for complicated skin infections.
Indication information is not present in the provided label excerpts (only mortality and pneumonia limitations are included).
Tigecycline is an intravenous glycylcycline antibiotic for intra-abdominal infections.
Indication information is not present in the provided label excerpts (only mortality and pneumonia limitations are included).
Tigecycline trials showed 5.5% all-cause mortality versus 4.5% in comparators.
The excerpt’s comparator mortality rates differ from 5.5% vs 4.5%.
Contradictions
Low
AI Statement
Tigecycline trials showed 5.5% all-cause mortality versus 4.5% in comparators.
Label Reference
Label excerpt 5.1: death occurred in 4.0% (150/3788) of TYGACIL vs 3.0% (110/3646) of comparator drugs in all 13 Phase 3 and 4 trials; and 2.5% vs 1.8% for mortality in trials for approved indications. The AI’s 5.5% vs 4.5% conflicts with the provided label figures.
Important Omissions
No accurate reporting of the label’s pooled adjusted risk difference for all-cause mortality (0.6% with 95% CI 0.1 to 1.2) is included in the assessed AI claims set.
Importance:
Moderate
No label-consistent statement that the cause of the mortality imbalance has not been established.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The AI includes several unsupported/incorrect claims outside the provided label excerpts; additionally it provides an all-cause mortality comparison (5.5% vs 4.5%) that conflicts with the label’s provided figures. Some mortality interpretation claims attribute causality (septic shock/respiratory failure) despite the label stating the cause is not established.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Partially Aligned
Primary Issue
Multiple mortality statistics and etiologic explanations are not supported by the provided label excerpts, and one mortality figure conflicts with label-provided rates.
Suggested Improvement
For mortality/all-cause mortality: use the label-provided death rates (4.0% vs 3.0% in Phase 3/4 comparator trials) and the pooled adjusted risk difference (0.6%, 95% CI 0.1 to 1.2), and avoid attributing the cause of imbalance to specific mechanisms because the label states the cause has not been established.